drugset / Trial / NCT03931551
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2\[+\], BRCA-mutated advanced breast cancer
Timeline
- Start
- 2019-04-30
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
Outcome
Outcome not reported
Stopped (Enrollment): “Very slow recruitment due to subject profile”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 600 mg | Intravenous |